Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Analyst Ratings
Strong Buy
11 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRAX Stock 12 Month Forecast
Average Price Target
$106.73
▲(116.71% Upside)
| Highest Price Target$270.00 | Average Price Target$106.73 | Lowest Price Target$33.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
$80
Buy
62.44%
Upside
Reiterated
09/22/25
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Praxis Precision Medicines (NASDAQ: PRAX) and Sanofi (Other OTC: SNYNF)We see an attractive entry point for PRAX at current levels for the following reasons: 1. V ormatrigine's differentiation based on RADIANT alone underappreciated; full data from RADIANT, POWER 1, 2 and 3 could further differentiate profile and expand market potential 2. Relutrigine has good chance of success in SCN2A/8A, in EMBOLD Ph 3 (1H26 data), based on positive Ph 2, with potential to address the much larger DEE market with EMERALD Ph 3 3. Elsunersen should build on prior OL data in SCN2A GoF, in EMBRA VE (1H26 data), which can also derisk the SOLIDUS ASO platform 4. At a <$900M market cap PRAX's valuation is attractive with multiple shots on goal which could collectively drive >$4B in peak sales 5.
H.C. Wainwright
$115
Buy
133.50%
Upside
Reiterated
09/17/25
Piper Sandler
$270
Buy
448.22%
Upside
Reiterated
09/17/25
JonesTrading
$83
Buy
68.53%
Upside
Initiated
09/17/25
Truist Financial
―
Buy
―
Reiterated
09/09/25
TD Cowen
$61
Buy
23.86%
Upside
Reiterated
09/03/25
LifeSci Capital
$117
Buy
137.56%
Upside
Initiated
09/03/25
Jefferies
$65
Buy
31.98%
Upside
Reiterated
09/02/25
Promising Outlook for Praxis Precision Medicines: Buy Rating Affirmed on Strong Drug Efficacy and Financial PositionWe like the stock setup heading into add'l Phase II/III datasets as early as YE:25, with Q2 cash of $447M ($21/sh) providing some valuation support. At IEC 2025, new open-label Phase II RADIANT data incrementally reinforces vormatrigine's efficacy signal seen in focal epilepsy. The IEC update is still based on the Aug 2025 data cut on N=37 (i.e. shared last month), but we do have more granular efficacy data, such as % seizure reduction by subgroup and efficacy responder rates (including complete seizure freedom). (1) For context, the 8-week, open-label Phase II RADIANT showed a -56% absolute seizure reduction with 30mg QD (N=37), which looks on par with the most efficacious epilepsy drugs in pbo-controlled studies.
Guggenheim
$155
Buy
214.72%
Upside
Reiterated
08/12/25
Chardan Capital
$80
Buy
62.44%
Upside
Reiterated
08/05/25
Wedbush
$28→$33
Sell
-32.99%
Downside
Reiterated
08/04/25
Oppenheimer
$97→$115
Buy
133.50%
Upside
Reiterated
07/08/25
Robert W. Baird
$73→$76
Buy
54.31%
Upside
Reiterated
05/05/25
Deutsche Bank
$111→$65
Buy
31.98%
Upside
Reiterated
03/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
$80
Buy
62.44%
Upside
Reiterated
09/22/25
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Praxis Precision Medicines (NASDAQ: PRAX) and Sanofi (Other OTC: SNYNF)We see an attractive entry point for PRAX at current levels for the following reasons: 1. V ormatrigine's differentiation based on RADIANT alone underappreciated; full data from RADIANT, POWER 1, 2 and 3 could further differentiate profile and expand market potential 2. Relutrigine has good chance of success in SCN2A/8A, in EMBOLD Ph 3 (1H26 data), based on positive Ph 2, with potential to address the much larger DEE market with EMERALD Ph 3 3. Elsunersen should build on prior OL data in SCN2A GoF, in EMBRA VE (1H26 data), which can also derisk the SOLIDUS ASO platform 4. At a <$900M market cap PRAX's valuation is attractive with multiple shots on goal which could collectively drive >$4B in peak sales 5.
H.C. Wainwright
$115
Buy
133.50%
Upside
Reiterated
09/17/25
Piper Sandler
$270
Buy
448.22%
Upside
Reiterated
09/17/25
JonesTrading
$83
Buy
68.53%
Upside
Initiated
09/17/25
Truist Financial
―
Buy
―
Reiterated
09/09/25
TD Cowen
$61
Buy
23.86%
Upside
Reiterated
09/03/25
LifeSci Capital
$117
Buy
137.56%
Upside
Initiated
09/03/25
Jefferies
$65
Buy
31.98%
Upside
Reiterated
09/02/25
Promising Outlook for Praxis Precision Medicines: Buy Rating Affirmed on Strong Drug Efficacy and Financial PositionWe like the stock setup heading into add'l Phase II/III datasets as early as YE:25, with Q2 cash of $447M ($21/sh) providing some valuation support. At IEC 2025, new open-label Phase II RADIANT data incrementally reinforces vormatrigine's efficacy signal seen in focal epilepsy. The IEC update is still based on the Aug 2025 data cut on N=37 (i.e. shared last month), but we do have more granular efficacy data, such as % seizure reduction by subgroup and efficacy responder rates (including complete seizure freedom). (1) For context, the 8-week, open-label Phase II RADIANT showed a -56% absolute seizure reduction with 30mg QD (N=37), which looks on par with the most efficacious epilepsy drugs in pbo-controlled studies.
Guggenheim
$155
Buy
214.72%
Upside
Reiterated
08/12/25
Chardan Capital
$80
Buy
62.44%
Upside
Reiterated
08/05/25
Wedbush
$28→$33
Sell
-32.99%
Downside
Reiterated
08/04/25
Oppenheimer
$97→$115
Buy
133.50%
Upside
Reiterated
07/08/25
Robert W. Baird
$73→$76
Buy
54.31%
Upside
Reiterated
05/05/25
Deutsche Bank
$111→$65
Buy
31.98%
Upside
Reiterated
03/03/25
Best Analysts Covering Praxis Precision Medicines
1 Month
xxx
Success Rate
9/14 ratings generated profit
Average Return
+8.07%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +8.07% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+15.84%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +15.84% per trade.
1 Year
Success Rate
13/27 ratings generated profit
Average Return
+74.33%
reiterated a buy rating 10 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +74.33% per trade.
2 Years
xxx
Success Rate
16/27 ratings generated profit
Average Return
+51.20%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 59.26% of your transactions generating a profit, with an average return of +51.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRAX Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
13
10
12
12
15
Buy
1
2
4
5
8
Hold
6
6
10
10
11
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
20
18
26
28
35
Each month's total comprises the sum of three months' worth of ratings.
PRAX Financial Forecast
PRAX Stock Forecast FAQ
What is PRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Praxis Precision Medicines’s 12-month average price target is 106.73.
What is PRAX’s upside potential, based on the analysts’ average price target?
Praxis Precision Medicines has 116.71% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRAX a Buy, Sell or Hold?
Praxis Precision Medicines has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 1 sell ratings.
What is Praxis Precision Medicines’s price target?
The average price target for Praxis Precision Medicines is 106.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $270.00 ,the lowest forecast is $33.00. The average price target represents 116.71% Increase from the current price of $49.25.
The highest analyst price target is $270.00 ,the lowest forecast is $33.00. The average price target represents 116.71% Increase from the current price of $49.25.
What do analysts say about Praxis Precision Medicines?
Praxis Precision Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of PRAX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.